Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Kate Kelley, Robin; Sangro, Bruno; Proctor Harris, William; Ikeda, Masafumi; Okusaka, Takuji; Kang, Yoon‐Koo; Qin, Shukui; Tai, David; Yeong Lim, Ho; Yau, Thomas; Peng Yong, Wei; Cheng, Ann‐Lii; Gasbarrini, Antonio; Damian, Silvia; Bruix, Jordi; J. Borad, Mitesh; C. Bendell, Johanna; Kim, Tae‐You; Standifer, Nathan; He, Philip; Makowsky, Mallory; Negro, Alejandra; Kudo, Masatoshi; K. Abou‐Alfa, Ghassan

doi:10.1200/jco.20.03555

Public

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Published in Journal of Clinical Oncology • Jul 22, 2021

Authors:

Robin Kate Kelley

Bruno Sangro

William Proctor Harris

Abstract

PURPOSE: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including ...

Subject

Tremelimumab

Durvalumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!